| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;116:685.)
© 2007 American Heart Association, Inc.
Issue Highlights
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
 |
REGRESSION OF ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY DURING ANTIHYPERTENSIVE THERAPY AND REDUCTION IN SUDDEN CARDIAC DEATH: THE LIFE STUDY, by Wachtell et al. |
|---|
ECG-detected left ventricular hypertrophy, one of the original Framingham "factors of risk" for coronary heart disease, is also a risk factor for sudden death and major nonfatal cardiovascular events. In this issue, Wachtell and colleagues use the extensive data from the Losartan Intervention for Events (LIFE) trial of >9000 patients with hypertension and ECG left ventricular hypertrophy to address whether regression of ECG markers of the left ventricular hypertrophy (voltage) is associated with reduced risk of sudden death. They confirm the importance of ECG left ventricular hypertrophy and provide new data that reduction in voltage was associated with lower risk of sudden death. See p 700.
|
INCIDENCE AND PREDICTORS OF DRUG-ELUTING STENT THROMBOSIS DURING AND AFTER DISCONTINUATION OF THIENOPYRIDINE TREATMENT, by Airoldi et al. |
|---|
Drug-eluting stents have been shown to reduce restenosis in randomized trials and in registries that represent a broader spectrum of patients. Recently, it has been shown that very late stent thrombosis is increased in the broader group of patients receiving drug-eluting stents. The prolonged use of dual antiplatelet therapy has been suggested as a potential means of reducing this late complication. This prospective observational study followed 3021 patients who received a drug-eluting stent. At 18 months, stent thrombosis was observed in 1.9% of patients. Forty-two patients developed stent thrombosis within 6 months; and 16, between 6 and 18 months. On multivariable analysis, discontinuation of thienopyridine therapy was the strongest predictor of stent thrombosis within the first 6 months (hazard ratio, 13.74; P< 0.001). No obvious relationship was evident from discontinuation of thienopyridine therapy after 6 months, but due to the small number
Related Articles:
Circulation 2007 116: 696-699.
Circulation 2007 116: e139-e141.
Circulation 2007 116: e142-e143.
Circulation 2007 116: e144-e145.
Circulation 2007 116: e146.
Circulation 2007 116: 700-705.
Circulation 2007 116: 755-763.